

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

WILLIAMS et al.

Serial No. 10/622,134

Filed: July 18, 2003

For: EOTAXIN: EOSINOPHIL CHEMOTACTIC CYTOKINE



Confirmation No. 2826

Atty. Ref.: 550-453

Group: 1646

Examiner: Unassigned

* * * * *

November 14, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**Office of Initial Patent Examination's
Filing Receipt Corrections**

Sir:

REQUEST FOR CORRECTION OF FILING RECEIPT

Attached is an Amendment correcting the cross-reference to the prior applications. Request is hereby made for a corrected Filing Receipt deleting the asterisk and reference to (*) Data provided by applicant is not consistent with PTO records.

Respectfully submitted,

NIXON & VANDERHYTE P.C.

By: _____

A handwritten signature in black ink, appearing to read "B. J. Sadoff", written over a horizontal line.

B. J. Sadoff
Reg. No. 36,663

BJS:plb
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-41000

550-453
355

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/622,134	07/18/2003	1646	0.00	550-453	7	23	2

23117
 NIXON & VANDERHYE, PC
 1100 N GLEBE ROAD
 8TH FLOOR
 ARLINGTON, VA 22201-4714



CONFIRMATION NO. 2826

FILING RECEIPT



OC000000011214871

Date Mailed: 11/07/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Timothy J. Williams, London, UNITED KINGDOM;
 Peter J. Jose, London, UNITED KINGDOM;
 David A. Griffiths-Johnson, London, UNITED KINGDOM;
 John J. Hsuan, London, UNITED KINGDOM;

Assignment For Published Patent Application

IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE;

Domestic Priority data as claimed by applicant

This application is a DIV of 09/291,038 04/14/1999 PAT 6,635,251
 which is a CON of 08/615,232 08/13/1996 PAT 5,993,814 *
 which is a 371 of PCT/GB94/02006 09/14/1994
 (*)Data provided by applicant is not consistent with PTO records.

Foreign Applications

UNITED KINGDOM 9318984.3 09/14/1993
 UNITED KINGDOM 9408602.2 04/29/1994
 UNITED KINGDOM PCT/GB94/02006 09/14/1994

If Required, Foreign Filing License Granted: 11/07/2003

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

Eotaxin : eosinophil chemotactic cytokine

Preliminary Class

530

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).